AbbVie Inc. (NYSE:ABBV) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of AbbVie Inc. (NYSE:ABBV) have received a consensus recommendation of “Moderate Buy” from the twenty-four analysts that are presently covering the firm, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation, thirteen have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $245.8421.

Several equities analysts recently issued reports on the stock. Piper Sandler reissued an “overweight” rating and set a $289.00 price target (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Erste Group Bank cut shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and raised their price target for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Morgan Stanley increased their target price on AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Finally, Guggenheim lifted their price target on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th.

Institutional Investors Weigh In On AbbVie

Several large investors have recently bought and sold shares of the company. Triumph Capital Management acquired a new position in AbbVie in the 3rd quarter worth $193,000. Advisors Management Group Inc. ADV bought a new position in shares of AbbVie during the third quarter worth about $242,000. AIA Group Ltd lifted its stake in AbbVie by 132.5% in the 3rd quarter. AIA Group Ltd now owns 26,837 shares of the company’s stock valued at $6,214,000 after acquiring an additional 15,295 shares in the last quarter. Lindenwold Advisors INC boosted its position in AbbVie by 1.0% during the 3rd quarter. Lindenwold Advisors INC now owns 15,635 shares of the company’s stock worth $3,620,000 after acquiring an additional 148 shares during the last quarter. Finally, Mirabella Financial Services LLP grew its stake in shares of AbbVie by 154.7% during the 3rd quarter. Mirabella Financial Services LLP now owns 32,899 shares of the company’s stock worth $7,602,000 after acquiring an additional 19,980 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of AbbVie stock opened at $230.07 on Friday. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. The company has a market cap of $406.63 billion, a PE ratio of 174.30, a price-to-earnings-growth ratio of 1.31 and a beta of 0.36. The firm has a fifty day moving average price of $226.73 and a two-hundred day moving average price of $212.57. AbbVie has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the prior year, the firm posted $3.00 EPS. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts expect that AbbVie will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. AbbVie’s payout ratio is 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.